Summary of OrthoPediatrics Conference Call Company Overview - **Company**: OrthoPediatrics - **Industry**: Pediatric Orthopedics - **Key Executives Present**: David Bailey (President and CEO), Joe Hauser (President of Trauma and Deformity, OPSB) Key Financial Highlights - **Q4 Performance**: Strong demand for Trauma and Deformity (T&D) implants in the U.S. and internationally, with significant growth in scoliosis products driven by the deployment of 7D technology and early procedures with VerteGlide [4][10] - **Free Cash Flow**: Achieved $10 million in free cash flow for Q4, marking the first quarter of positive cash flow [5] - **2026 Guidance**: Projected top-line growth of 11%-13%, with an adjusted EBITDA of $25 million and at least break-even cash flow [8] Business Segments Trauma and Deformity (T&D) - **Market Position**: T&D is the foundational product line for OrthoPediatrics, with over 40 systems in major children's hospitals across the U.S. [30] - **Competitive Landscape**: Limited competition focused solely on pediatrics, allowing for easier adoption of new products [32] - **New Product Launches**: Anticipated launches include the 3P Hip System and a Small-Mini System, with a goal of at least one major system launch annually [65][66] OrthoPediatrics Specialty Bracing (OPSB) - **Market Opportunity**: Estimated total addressable market (TAM) of $500 million, with current penetration around 10% [90] - **Growth Strategy**: Focus on expanding into new geographical markets and leveraging existing relationships with hospitals [92][94] - **Profitability**: OPSB has lower gross margins but higher contribution margins due to lower selling costs and no capital deployment [99] Scoliosis - **Market Share**: Represents about 25% of global revenue, with less than 20% market share in children's hospitals [111] - **Competitive Advantage**: Focus on early onset scoliosis with limited competition and investment in technology development [118] - **Key Products**: VerteGlide and RESPONSE ribbon Pelvic device are part of a comprehensive portfolio aimed at addressing significant clinical needs [121] Strategic Insights - **Regulatory Approvals**: Recent EU MDR approvals are expected to enhance international growth, particularly in the scoliosis and trauma markets [14] - **Market Dynamics**: Competitors are withdrawing from pediatric products due to regulatory costs, providing OrthoPediatrics with a unique opportunity to capture market share [33][37] - **Long-Term Growth**: The company is positioned for sustained growth with a focus on innovative product development and expanding its market presence [125] Conclusion OrthoPediatrics is strategically positioned in the pediatric orthopedic market with strong financial performance, a robust product pipeline, and significant growth opportunities in both existing and new markets. The company's focus on specialized pediatric products and its unique market position differentiate it from broader orthopedic competitors.